Q32 Bio (QTTB) announced that the company has dosed the first patients in both the Part A open-label extension and Part B of the SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with alopecia areata. The trial is intended to support advancement into pivotal trials upon completion, pending review of the results. Q32 Bio expects to report topline data from SIGNAL-AA Part B in the first half of 2026.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QTTB: